Download PDF
Klin Monbl Augenheilkd 2006; 223(11): 908-913
DOI: 10.1055/s-2006-927095
Klinische Studie

© Georg Thieme Verlag KG Stuttgart · New York

Arterielle okuläre Gefäßverschlüsse bei systemischer venöser Thrombophilie - 2 Kasuistiken

Arterial Ocular Occlusion Associated with Systemic Venous Thrombophilia - 2 Case ReportsD. Leifert1 , C. Auw-Hädrich2 , J. A. Leifert3
  • 1Universitäts-Augenklinik Basel (Direktor: Prof. J. Flammer)
  • 2Universitäts-Augenklinik Freiburg (Direktor: Prof. Th. Reinhard)
  • 3Universitätsklinik Freiburg, Abt. Medizin I (Direktor: Prof. R. Mertelsmann)
Further Information

Publication History

Eingegangen: 15.9.2005

Angenommen: 12.6.2006

Publication Date:
28 November 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund: Arterielle okuläre Gefäßverschlüsse bei gesunden, jungen Männern sind ungewöhnlich. Über das Ausmaß der adäquaten Thrombophilie-Diagnostik herrscht angesichts der vielfach widersprüchlichen Studienergebnisse erhebliche Verunsicherung. Wir berichten über den Verlauf der Thrombophilie-Diagnostik bei zwei jungen Patienten mit nichtarteriitischer anteriorer ischämischer Optikusneuropathie (NAION) bzw. Arterienastverschluss (AAV). Kasuistik: Wir berichten über zwei junge, bis dahin gesunde Männer. Wegen der festgestellten Perfusionsstörung im arteriellen Gefäßbett hatte eine erste Therapie-Empfehlung bei beiden in thrombozytenaggregationshemmenden Wirkstoffen bestanden. Die Suche nach Emboliequellen im arteriellen Stromgebiet ergab bei beiden ein signifikantes kardiales bzw. intrapulmonales venösarterielles Shuntvolumen. Das daraufhin in die Wege geleitete Thrombophilie-Screening nach Risikofaktoren für Verschlüsse des venösen Gefäßbettes ergab bei beiden eine homozygote bzw. heterozygote Faktor-V-Leiden-Mutation sowie eine Hyperhomocysteinämie. Schlussfolgerungen: Beide Fälle zeigen, dass bei Auftreten arterieller okulärer Gefäßkomplikationen die Suche nach Shuntvolumina unerlässlich ist und gegebenenfalls zusätzlich zu den typischen Risikofaktoren für arterielle Gefäßverschlüsse ein Screening nach venösen Thrombophilie-Faktoren angeschlossen werden muss.

Abstract

Background: Arterial ocular occlusions in apparently healthy young men are unusual. Because of inconsistent study results there is a great amount of insecurity with respect to the reasonable diagnostic approach in such a scenario. We report on the process of diagnostic steps in two young men with arterial ocular occlusion such as non-arteritic optic neuropathy (NAION) and branch retinal arterial occlusion (BRAO). Case Report: Here, we report on two hitherto healthy young men who suffered from ocular arterial occlusions. Because of the apparent arterial perfusion deficit at first thrombocyte aggregation-inhibiting substances were recommended. On searching for the underlying embolic source in both men a significant arterial-venous cardiac and pulmonary shunt volume was identified. Additional screening for risk factors for venous thrombosis resulted in the identification of Factor V Leiden as well as hyperhomocysteinemia. Conclusion: These two cases stress the importance to exclude possible arterial-venous shunts and, if identified, the need to search for additional risk factors for venous thrombosis in patients with arterial embolic ocular disease.

Schlüsselwörter

okuläre Gefäßverschlüsse - gekreuzte Embolie - arteriovenöser Shunt - Thrombophilie

Key words

vascular ocular occlusion - paradoxical embolism - arterial-venous shunt - thrombophilia

Literatur

  • 1 Almawi W Y, Tamim H, Kreidy R. et al . A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis.  J Thromb Thrombolys. 2005;  19 189-196
    PubMedGoogle Scholar
  • 2 Arsene S, Delahousse B, Regina S. et al . Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age.  Thromb Haemost. 2005;  94 101-106
    PubMedGoogle Scholar
  • 3 B-Vitamin T reatment Trialists’ Collaboration . Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials.  Am Heart J. 2006;  151 (2) 282-287
    CrossrefPubMedGoogle Scholar
  • 4 Ben-Ami R, Zeltser D, Leibowitz I. et al . Retinal artery occlusion in a patient with factor V Leiden and prothrombin G20210A mutations.  Blood Coagul Fibrinolysis. 2002;  13 (1) 57-59
    CrossrefPubMedGoogle Scholar
  • 5 Bertina R M, Koeleman B PC, Koster T. et al . Mutation in the blood coagulation factor V associated with resistance to activated protein C.  Nature. 1994;  360 64-67
    PubMedGoogle Scholar
  • 6 Biller J, Johnson M R, Adams H P Jr. et al . Further observations on cerebral or retinal ischemia in patients with right-left intracardiac shunts.  Arch Neurol. 1987;  44 (7) 740-743
    PubMedGoogle Scholar
  • 7 Blom H J. Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine beta-synthase and 5,10-methylenetetrahydrofolate reductase.  Eur J Pediatr. 2000;  159 (Suppl 3) S208-212
    PubMedGoogle Scholar
  • 8 Brown B A, Marx J L, Ward T P. et al . Homocysteine: a risk factor for retinal venous occlusive disease.  Ophthalmology. 2002;  109 (2) 287-290
    CrossrefPubMedGoogle Scholar
  • 9 Cahill M T, Stinnett S S, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease.  Am J Ophthalmol. 2003;  136 (6) 1136-1150
    CrossrefPubMedGoogle Scholar
  • 10 Cahill M, Karabatzaki M, Donoghue C. et al . Thermolabile MTHFR genotype and retinal vascular occlusive disease.  Br J Ophthalmol. 2001;  85 (1) 88-90
    CrossrefPubMedGoogle Scholar
  • 11 Ciardella A P, Yanuzzi L A, Freund K B. et al . Factor V Leiden, activated protein C resistance, and retinal vein occlusion.  Retina. 1998;  18 (4) 308-315
    PubMedGoogle Scholar
  • 12 Cushman M. Inherited risk factors for venous thrombosis.  Hematology (Am Soc Hematol Educ Program). 2005;  452-457
    CrossrefPubMedGoogle Scholar
  • 13 Cushman M, Rosendaal F R, Psaty B M. et al . Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the cardiovascular health study.  Thromb Haemost. 1998;  79 912-915
    PubMedGoogle Scholar
  • 14 Dahlbäck B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognised mechanism characterised by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci USA. 1993;  90 1004-1008
    CrossrefPubMedGoogle Scholar
  • 15 den Heijer M, Rosendaal F R, Blom H J. et al . Hyperhomocysteinemia and venous thrombosis: a meta-analysis.  Thromb Haemost. 1998;  80 874-877
    PubMedGoogle Scholar
  • 16 Dorweiler B, Neufang A, Kasper-Koenig W. et al . Arterial embolism to the upper extremity in a patient with factor V Leiden mutation (APC resistance).  Angiology. 2003;  54 125-130
    PubMedGoogle Scholar
  • 17 Dudman N P. An alternative view of homocysteine.  Lancet. 1999;  354 (9195) 2072-2074
    CrossrefPubMedGoogle Scholar
  • 18 Faude S, Faude F, Siegemund A. et al . Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group.  Ophthalmologe. 1999;  96 (9) 549-599
    PubMedGoogle Scholar
  • 19 Fegan C D. Central retinal vein occlusion and thrombophilia.  Eye. 2002;  16 98-106
    CrossrefPubMedGoogle Scholar
  • 20 Foerch C, Kessler K R, Sitzer M. Brain infarctions caused by paradoxical embolism during long-distance flights.  Dtsch Med Wochenschr. 2003;  128 196-198
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Fowler B. Homocysteine: Overview of Biochemistry, Molecular Biology, and Role in Disease Processes.  Semin Vasc Med. 2005;  5 (2) 77-86
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Frosst P, Blom H J, Milos R. et al . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.  Nat Genet. 1995;  10 111-113
    CrossrefPubMedGoogle Scholar
  • 23 Gautier J C, Durr A, Koussa S. et al . Paradoxal cerebral embolism: role of patent oval foramen.  Bull Acad Natl Med. 1990;  174 (7) 1031-1038
    PubMedGoogle Scholar
  • 24 Gellekink H, den Heijer M, Heil S G. et al . Genetic determinants of plasma total homocysteine.  Semin Vasc Med. 2005;  5 (2) 98-109
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Gerling J, Janknecht P, Hansen L L. et al . Diameter of the optic nerve in idiopathic optic neuritis and in anterior ischemic optic neuropathy.  Int Ophthalmol. 1997;  21 (3) 131-135
    CrossrefPubMedGoogle Scholar
  • 26 Glueck C J, Wang P, Bell H. et al . Nonarteritic anterior ischemic optic neuropathy: associations with homozygosity for the C677T methylenetetrahydrofolate reductase mutation.  J Lab Clin Med. 2004;  143 (3) 184-192
    CrossrefPubMedGoogle Scholar
  • 27 Gottlieb J L, Blice J P, Mestichelli B. et al . Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults.  Arch Ophthalmol. 1998;  116 577-579
    PubMedGoogle Scholar
  • 28 Gomez F, Rodriguez A, Rivas J. et al . Mesenteric arterial thrombosis due to activated protein C resistance (factor V Leiden).  Surgery. 2000;  128 494-496
    PubMedGoogle Scholar
  • 29 Graham S L, Goldberg I, Murray B. et al . Activated protein C resistance - low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion.  Aust N Z Ophthalmol. 1996;  24 199-205
    PubMedGoogle Scholar
  • 30 Greiner K, Hafner G, Prellwitz W. et al . Hereditary disorders of the protein C system in central artery and branch arteriolar occlusions.  Klin Monatsbl Augenheilkd. 1999;  215 (1) 33-36
    PubMedGoogle Scholar
  • 31 Greiner K, Peetz D, Winkgen A. et al . Genetic thrombophilia in patients with retinal vascular occlusion.  Int Ophthalmol. 1999;  23 155-160
    CrossrefPubMedGoogle Scholar
  • 32 Grossmann R, Schwender S, Geisen U. et al . CBS 844ins68, MTHFR TT677 and EPCR 4031ins23 genotypes in patients with deep-vein thrombosis.  Thromb Res. 2002;  107 (1 - 2) 13-15
    CrossrefPubMedGoogle Scholar
  • 33 Hanson N Q, Aras O, Yang F. et al . C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease.  ClinChem. 2001;  47 (4) 661-666
    PubMedGoogle Scholar
  • 34 Hodgkins P R, Perry D J, Sawcer S J. et al . Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion.  Eye. 1995;  9 760-762
    PubMedGoogle Scholar
  • 35 Hsu T S, Hsu L A, Chang C J. et al . Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case-control study.  Thromb Res. 2001;  102 (5) 387-395
    CrossrefPubMedGoogle Scholar
  • 36 Huisman M V, Rosendaal F. Thrombophilia.  Curr Opin Hematol. 1999;  6 (5) 291-297
    CrossrefPubMedGoogle Scholar
  • 37 Janssen M C, den Heijer M, Cruysberg J R. et al . Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors.  Thromb Haemost. 2005;  93 (6) 1021-1026
    PubMedGoogle Scholar
  • 38 Karttunen V, Hiltunen L, Rasi V. et al . Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale.  Blood Coagul Fibrinolysis. 2003;  14 (3) 261-268
    CrossrefPubMedGoogle Scholar
  • 39 Kawasaki A, Purvin V A, Burgett R A. Hyperhomocysteinaemia in young patients with non-arteritic anterior ischaemic optic neuropathy.  Br J Ophthalmol. 1999;  83 (11) 1287-1290
    CrossrefPubMedGoogle Scholar
  • 40 Kim D, Saver J L. Patent foramen ovale and stroke: what we do and don’t know.  Rev Neurol Dis. 2005;  2 (1) 1-7
    PubMedGoogle Scholar
  • 41 Kluijtmans L AJ, Kastelein J JP, Lindemans J. et al . Thermolabile methylenetetra-hydrofolate reductase in coronary artery disease.  Circulation. 1997;  96 2573-2577
    PubMedGoogle Scholar
  • 42 Kluijtmans L A, Whitehead A S. Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease; evidence that all three MTHFR C677T genotypes confer different levels of risk.  Eur Heart J. 2001;  22 (4) 294-299
    CrossrefPubMedGoogle Scholar
  • 43 Koster T, Rosendaal F RR, de Ronde H. et al . Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.  Lancet. 1993;  342 1503-1506
    CrossrefPubMedGoogle Scholar
  • 44 Larsson J, Sellman A, Bauer B. Activated protein C resistance in patients with central retinal vein occlusion.  Br J Ophthalmol. 1997;  81 832-834
    PubMedGoogle Scholar
  • 45 Linna, Ylikorkala A, Kontula K. et al . Prevalence of factor V leiden in young adults with retinal vein occlusion.  Thromb Haemost. 1997;  77 212-224
    PubMedGoogle Scholar
  • 46 Longstreth W T Jr, Rosendaal F R, Siscovick D S. et al . Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A).  Stroke. 1998;  29 577-580
    PubMedGoogle Scholar
  • 47 Marcucci R, Giusti B, Betti I. et al . Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion.  Thromb Res. 2003;  110 (1) 7-12
    CrossrefPubMedGoogle Scholar
  • 48 Marcucci R, Bertini L, Giusti B. et al . Thrombophilic risk factors in patients with central retinal vein occlusion.  Thromb Haemost. 2001;  86 (3) 772-776
    PubMedGoogle Scholar
  • 49 van der Meer F JM, Koster T, Vandenbroucke J P. et al . The Leiden Thrombophilia Study (LETS).  Thromb Haemost. 1997;  78 631-635
    PubMedGoogle Scholar
  • 50 Middendorf K, Gohring P, Huehns T Y. et al . Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.  Am Heart J. 2004;  147 (5) 897-904
    CrossrefPubMedGoogle Scholar
  • 51 Pianka P, Almog Y, Man O. et al . Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion.  Ophthalmology. 2000;  107 (8) 1588-1592
    CrossrefPubMedGoogle Scholar
  • 52 Ray J G. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease.  Arch Intern Med. 1998;  158 2101-2106
    CrossrefPubMedGoogle Scholar
  • 53 Rees D C, Cox M, Clegg J B. World distribution of Factor V Leiden.  Lancet. 1995;  346 1133-1134
    CrossrefPubMedGoogle Scholar
  • 54 Salomon O, Moisseiev J, Rosenberg N. et al . Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vascular occlusion.  Blood Coagul Fibrinolysis. 1998;  9 617-622
    PubMedGoogle Scholar
  • 55 Salomon O, Huna-Baron R, Kurtz S. et al . Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy.  Ophthalmology. 1999;  106 (4) 739-742
    CrossrefPubMedGoogle Scholar
  • 56 Schnyder G, Roffi M, Pin R. et al . Decreased rate of coronary restenosis after lowering of plasma homocysteine levels.  N Engl J Med. 2001;  345 1593-1600
    PubMedGoogle Scholar
  • 57 De Stefano V, Chiusolo P, Paciaroni K. et al . Epidemiology of Factor V Leiden: clinical implications.  Semin Thromb Hemost. 1998;  24 367-379
    PubMedGoogle Scholar
  • 58 Steuber C, Panzner B, Steuber T. et al . Open foramen ovale in patients with arterial vascular occlusions of the retina and optic nerve.  Curr Opin Ophthalmol. 1997;  8 (3) 3-7
    PubMedGoogle Scholar
  • 59 Tobis M J, Azarbal B. Does patent foramen ovale promote cryptogenic stroke and migraine headache?.  Tex Heart Inst J. 2005;  32 (3) 362-365
    PubMedGoogle Scholar
  • 60 Di Tullio M, Sacco R L, Gopal A. et al . Patent foramen ovale a sa risk factor for crytogenic stroke.  Ann Intern Med. 2004;  164 (9) 950-956
    CrossrefPubMedGoogle Scholar
  • 61 Verdu A, Cazorla M R, Granados M A. et al . Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation.  Pediatric Neurology. 2001;  24 69-71
    CrossrefPubMedGoogle Scholar
  • 62 Wald D S, Law M, Morris J K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.  BMJ. 2002;  325 1202
    CrossrefPubMedGoogle Scholar
  • 63 Wald D S, Bishop L, Wald N J. et al . Randomised trial of folic acid supplementation on serum homocysteine levels.  Arch Intern Med. 2001;  161 695-700
    CrossrefPubMedGoogle Scholar
  • 64 Weger M, Renner W, Pinter O. et al . Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion.  Eye. 2003;  17 (6) 731-734
    CrossrefPubMedGoogle Scholar
  • 65 Weger M, Renner W, Steinbrugger I. et al . Role of thrombophilic gene polymorphisms in branch retinal vein occlusion.  Ophthalmology. 2005;  112 (11) 1910-1915
    CrossrefPubMedGoogle Scholar
  • 66 Weger M, Stanger O, Deutschmann H. et al . Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy.  Br J Ophthalmol. 2001;  85 (7) 803-806
    CrossrefPubMedGoogle Scholar
  • 67 Weger M, Stanger O, Deutschmann H. et al . Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.  Graefes Arch Clin Exp Ophthalmol. 2002;  240 (4) 286-290
    CrossrefPubMedGoogle Scholar
  • 68 Williamson T H, Rumley A, Lowe G DO. Blood viscosity, coagulation and activated protein C resistance in central retinal vein occlusion: a population controlled study.  Br J Ophthalmol. 1996;  80 203-208
    PubMedGoogle Scholar
  • 69 Wu L A, Malouf J F, Dearani J A. et al . Patent foramen ovale in cryptogenic stroke: current understanding and management options.  Arch Intern Med. 2004;  164 (9) 950-956
    CrossrefPubMedGoogle Scholar

Dr. med. Dorothee Leifert

Univ.-Augenspital Basel

Mittlere Str. 91

4056 Basel, Schweiz

Phone: ++41/61/2 65 87 37

Fax: ++41/61/2 65 87 44

Email: leifertd@uhbs.ch